Photo of Bill Hoon Chang, M.D., Ph.D.

Bill Hoon Chang M.D., Ph.D.

  • 5034185150
    • Associate Professor of Pediatrics, Division of Hematology and Oncology School of Medicine

Dr. Bill Chang is an associate professor in the Department of Pediatrics, Division of Hematology/Oncology and St. Baldrick’s Scholar. Dr. Chang completed his fellowship in 2006 at Doernbecher, where he received the Robert C. Neerhout Fellow Award, the Ruth L.  Kirschstein National Research Service Award and the National Childhood Cancer Foundation Research Fellowship (2005). He completed his pediatric residency and  M.D./Ph.D. programs at OHSU. Dr. Chang received his Ph.D. in neuroscience, where he focused on signaling mechanisms within the cell. He currently is a researcher of malignant transformations in pediatric oncology. His teaching responsibilities include: small group facilitator and preceptor, PCM; lectures, 3rd year SOM curriculum and fellows basic lectures; lectures, physician assistant pediatric lecture series.

  • Residency:

    • Pediatrics, Oregon Health & Science University, 2003
  • Fellowship:

    • Fellowship in pediatric hematology/oncology, Oregon Health & Science University, 2006
  • Certifications:

    • American Board of Pediatrics, 2003

Memberships and associations

  • American Academy of Pediatrics

Publications

  • "Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia." Experimental Hematology In: , Vol. 51, 01.07.2017, p. 71-82.e3.
  • "Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia." Blood  In: , Vol. 129, No. 11, 16.03.2017, p. e26-e37.
  • "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia." Science Translational Medicine In: , Vol. 8, No. 354, 354ra114, 31.08.2016.
  • "A phase i study of quizartinib combined with chemotherapy in relapsed childhood leukemia : A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study." Clinical Cancer Research In: , Vol. 22, No. 16, 15.08.2016, p. 4014-4022.
  • "Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia." Oncotarget  In: , Vol. 7, No. 51, 2016, p. 84214-84227.
  • "Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML)." Pediatric Blood and Cancer  In: , Vol. 62, No. 7, 01.07.2015, p. 1149-1154.
  • "Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes." Leukemia In: , 25.06.2015.
  • "Serum Exosome MicroRNA as a minimally-invasive early biomarker of AML." Scientific Reports  In: , Vol. 5, 11295, 12.06.2015.
  • "Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia." Pediatric Blood and Cancer In: , Vol. 62, No. 6, 01.06.2015, p. 1048-1054.
  • "Therapeutically targetable ALK mutations in leukemia." Cancer Research In: , Vol. 75, No. 11, 01.06.2015, p. 2146-2150.
  • "YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway." Journal of Hematology and Oncology In: , Vol. 8, No. 1, 39, 22.04.2015.
  • "Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia." Cancer Cell  In: , Vol. 27, No. 3, 09.03.2015, p. 409-425.
  • "Comparison of methods to identify aberrant expression patterns in individual patients : Augmenting our toolkit for precision medicine." Genome Medicine  In: , Vol. 5, No. 11, 103, 29.11.2013.
  • "TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia." Cancer Discovery In: , Vol. 3, No. 5, 05.2013, p. 564-577.
  • "Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening." Cancer Research In: , Vol. 73, No. 1, 01.01.2013, p. 285-296.
  • "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML." New England Journal of Medicine In: , Vol. 368, No. 19, 2013, p. 1781-1790.
  • "Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia." Cancer Cell In: , Vol. 22, No. 5, 13.11.2012, p. 656-667.
  • "Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia." Genome Research In: , Vol. 22, No. 10, 10.2012, p. 1833-1844.
  • "In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia." Pediatric Blood and Cancer In: , Vol. 59, No. 3, 09.2012, p. 576-579.
  • "Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph +ALL : A Children's Oncology Group (COG) study." British Journal of Haematology In: , Vol. 157, No. 4, 05.2012, p. 507-510.
  • "Targeting survivin and p53 in pediatric acute lymphoblastic leukemia." Leukemia In: , Vol. 26, No. 4, 04.2012, p. 623-632.
  • "RNAi screen for rapid therapeutic target identification in leukemia patients." Proceedings of the National Academy of Sciences of the United States of America In: , Vol. 106, No. 21, 26.05.2009, p. 8695-8700.
  • "Management of menstrual bleeding and cycle control after hematopoietic stem cell transplant." International Journal of Gynecology and Obstetrics In: , Vol. 100, No. 1, 01.2008, p. 76-77.
  • "A unique case of adolescent CD56-negative extranodal NK/T-cell lymphoma, nasal type." Pediatric and Developmental Pathology  In: , Vol. 11, No. 1, 01.2008, p. 50-54.
  • "p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint." Journal of Biological Chemistry  In: , Vol. 282, No. 13, 30.03.2007, p. 9678-9687.
  • "Chromosomes with delayed replication timing lead to checkpoint activation, delayed recruitment of Aurora B and chromosome instability." Oncogene In: , Vol. 26, No. 13, 22.03.2007, p. 1852-1861.
  • "Neuroblastoma Found in a 4-Year-Old After Rituximab Therapy for Opsoclonus-Myoclonus." Pediatric Neurology  In: , Vol. 35, No. 3, 09.2006, p. 213-215.
  • "Calcium/calmodulin-dependent protein kinase II inhibitor protein : Localization of isoforms in rat brain." Neuroscience In: , Vol. 102, No. 4, 14.02.2001, p. 767-777.
  • "Cellular Signaling through Multifunctional Ca 2+/Calmodulin-dependent Protein Kinase II." Journal of Biological Chemistry  In: , Vol. 276, No. 6, 09.02.2001, p. 3719-3722.
  • "Ca/calmodulin-dependent kinase II mediates simultaneous enhancement of gap-junctional conductance and glutamatergic transmission." Proceedings of the National Academy of Sciences of the United States of America In: , Vol. 95, No. 22, 27.10.1998, p. 13272-13277.

Additional information

Edit profile